Market Overview

Warner Chilcott Announces FDA Approval of DELZICOL

Related WCRX
Actavis, Warner Chilcott Receive FTC Clearance for Actavis' Proposed Acquisition of Warner Chilcott
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Profit Margin

Warner Chilcott plc (Nasdaq: WCRX) today announced that the United States Food and Drug Administration (FDA) has approved its new 400 mg mesalamine product indicated for the treatment of ulcerative colitis. The product will be marketed as DELZICOL™ (mesalamine) 400 mg delayed-release capsules. The Company anticipates that it will commercially launch DELZICOL in March 2013.

Posted-In: News FDA

 

Related Articles (WCRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters